Funded Startups in Lexington
Among the 40 most recent listings, the largest disclosed round is Alloy Therapeutics’ $40M Series E on 2026-04-15; that single figure sits far above the re…
Among the 40 most recent listings, the largest disclosed round is Alloy Therapeutics’ $40M Series E on 2026-04-15; that single figure sits far above the rest of the disclosed amounts in this slice (notably, after $40M the next-highest disclosed items include Triana Biomedicines at $120M on 2025-12-03 and Alzheon at $100M on 2024-06-12, while many rounds cluster in the $2M–$28M band). Date-wise, multiple clusters appear close together: 2024-04-22 Payhoa closed at $28M (Internet Services), and 2024-06-12 Alzheon closed at $100M (Biotechnology), both within ~2 months; in 2026, there are several late-June/May entries (Nortiva Bio $5M on 2026-06-18, iSpecimen $3M on 2026-05-08, and Alloy Therapeutics $40M on 2026-04-15).
Geographically, Lexington is split across state lines: Massachusetts entries recur (e.g., Nortiva Bio, iSpecimen, Triana Biomedicines, Hemanext, Carbon Biosciences), while Kentucky entries also recur heavily (e.g., VulnCheck is Massachusetts but many others such as Omega Ophthalmics $320K on 2026-01-15 and Avana Health $3M on 2025-12-19). Stage/signal mix is tilted toward uncertainty: 19 of 40 rows show “Series Unknown,” and 2 rows are explicitly “undisclosed” on amount, with the time window spanning from 2020-04-23 (Accent Therapeutics $63M) through 2026-06-18 (Nortiva Bio $5M).
Most recent rounds
40 shownRelated listings
Frequently asked
Which disclosed round is the size outlier in the most recent 40 entries, and where does it sit versus the rest?
The largest disclosed amount is Triana Biomedicines’ $120M on 2025-12-03 (Series B). It is an outlier relative to the many other disclosed rounds that fall in the low single-digit to a few tens of millions (e.g., iSpecimen $3M on 2026-05-08, VulnCheck $25M on 2026-02-17).
Is there a dense time window in Lexington-based rounds, or are dates evenly spread across 2020–2026?
Dates are not evenly spread: several entries cluster in mid-2024, including Payhoa at $28M on 2024-04-22 and Alzheon at $100M on 2024-06-12, with other 2024 activity nearby (e.g., Commonwealth $2M on 2024-05-15). The overall visible range runs from 2020-04-23 (Accent Therapeutics $63M) to 2026-06-18 (Nortiva Bio $5M).
Which Lexington states show the most repeat activity, based on the city/state shown in the rows?
Massachusetts appears repeatedly with multiple large biotech rounds, including Alloy Therapeutics ($40M on 2026-04-15), Triana Biomedicines ($120M on 2025-12-03), and Alzheon ($100M on 2024-06-12). Kentucky also recurs across sectors and stages (e.g., Omega Ophthalmics $320K on 2026-01-15 and Avana Health $3M on 2025-12-19), indicating cross-state concentration under the “Lexington” label.
Do any sectors dominate, and how does that relate to the biggest disclosed deals?
Biotechnology is the most frequent sector in the visible rows, appearing across multiple years and states, including Alloy Therapeutics ($40M on 2026-04-15), Triana Biomedicines ($120M on 2025-12-03), Alzheon ($100M on 2024-06-12), and Carbon Biosciences ($38M on 2022-06-21). The largest disclosed amounts in this list are also biotech-linked (Triana Biomedicines and Alzheon).
How much of the dataset lacks stage clarity, and does that obscure size comparisons?
Stage labeling is often unclear: 19 of 40 rows list “Series Unknown,” and amount is “undisclosed” in 2 rows. Despite that, disclosed amounts still show a wide spread with major outliers like Triana Biomedicines ($120M on 2025-12-03) compared with smaller disclosed entries such as Bluegrass Community and Technical College ($10K on 2026-04-01).
Which entries are among the most recent 90 days, and are their disclosed amounts clustered or varied?
In the most recent 90 days of the visible data (roughly from 2026-04-12 onward), entries include Alloy Therapeutics ($40M on 2026-04-15), Bluegrass Community and Technical College ($10K on 2026-04-01 is outside the 90-day window), iSpecimen ($3M on 2026-05-08), and Nortiva Bio ($5M on 2026-06-18). Disclosed amounts vary widely within this window, from Nortiva Bio at $5M (2026-06-18) to Alloy Therapeutics at $40M (2026-04-15) and VulnCheck at $25M (2026-02-17 is outside the strict 90-day cutoff).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.